Monobenzonum [INN-Latin] en es it fr

Monobenzonum [INN-Latin] Brand names, Monobenzonum [INN-Latin] Analogs

Monobenzonum [INN-Latin] Brand Names Mixture

  • No information avaliable

Monobenzonum [INN-Latin] Chemical_Formula


Monobenzonum [INN-Latin] RX_link

Monobenzonum [INN-Latin] fda sheet

Monobenzonum [INN-Latin] msds (material safety sheet)

Monobenzonum_[INN-Latin] MSDS

Monobenzonum [INN-Latin] Synthesis Reference

No information avaliable

Monobenzonum [INN-Latin] Molecular Weight

414.476 g/mol

Monobenzonum [INN-Latin] Melting Point

No information avaliable

Monobenzonum [INN-Latin] H2O Solubility


Monobenzonum [INN-Latin] State


Monobenzonum [INN-Latin] LogP


Monobenzonum [INN-Latin] Dosage Forms

Powder for solution

Monobenzonum [INN-Latin] Indication

For the treatment of infections caused by penicillinase-producing staphylococci which have demonstrated susceptibility to the drugs.

Monobenzonum [INN-Latin] Pharmacology

Nafcillin is a semisynthetic antibiotic substance derived from 6-amino-penicillanic acid. The drugs in this class are highly resistant to inactivation by staphylococcal penicillinase and are active against penicillinase-producing and non penicillinase-producing strains of Staphylococcus aureus. The penicillinase- resistant penicillins are active in vitro against a variety of other bacteria.

Monobenzonum [INN-Latin] Absorption

No information avaliable

Monobenzonum [INN-Latin] side effects and Toxicity

Serious toxicity is unlikely following large doses of nafcillin. Acute ingestion of large doses of nafcillin may cause nausea, vomiting, diarrhea and abdominal pain. Acute oliguric renal failure and hematuria may occur following large doses.

Monobenzonum [INN-Latin] Patient Information

Monobenzonum [INN-Latin] Organisms Affected

Enteric bacteria and other eubacteria